TIDES USA Recap
Last week, we attended TIDES USA. More than 130 visitors stopped by our booth or watched our joint presentation, Oligonucleotide Production Capacity Improvement with PolarDry® Electrostatic Drying (ESD) Technology, with Nitto Avecia.

23
May 24
Last week, we attended TIDES USA. More than 130 visitors stopped by our booth or watched our joint presentation, Oligonucleotide Production Capacity Improvement with PolarDry® Electrostatic Drying (ESD) Technology, with Nitto Avecia.
Here are a few of the key themes we heard about the challenges facing oligonucleotide and peptide producers during the show.
- • The product development and launch process is faster than it’s ever been. Getting to market fast offers critical advantages for establishing market leadership and realizing ROI.
- • Thermally sensitive peptide and oligonucleotide technologies offer exciting breakthroughs, but they require different manufacturing processes and regulatory considerations to bring to market.
- • Scaling from laboratory to production scale can be challenging and slow down the product introduction timeline.
These are the challenges that new technologies like Polar Dry® electrostatic drying can help therapeutics manufacturers solve. Electrostatic Drying technology offers a solution to improve the production capacity of oligonucleotides without sacrificing yield in large-scale production.
Did you miss the show? It’s not too late to get the highlights from our joint presentation and talk about your challenges. Simply email us to schedule a time that works for you.